Product Description
FOR46 is a fully human antibody conjugated to a potent payload, depending on the indication. Fortis Therapeutics is developing FOR46, a novel antibody-drug conjugate (ADC) against CD46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma.Ê (Sourced from: https://fortistx.com/for46-pipeline/)
Mechanisms of Action: CD46 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fortis Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FGCL-3246-112 | P2 |
Not yet recruiting |
Prostate Cancer |
2027-09-30 |
|
| NCI-2021-08857 | P2 |
Recruiting |
Prostate Cancer |
2027-03-31 |
|
| FOR46-001 | P1 |
Completed |
Prostate Cancer |
2023-11-16 |
25% |